ANI Pharma enhances generics and CDMO business through Novitium acquisition
The transaction expands ANI’s R&D pipeline and adds nine new customers to its growing CDMO business
ANI Pharmaceuticals has completed its acquisition of New Jersey-based Novitium Pharma, a move which sees the diversified biopharma company boost its development, manufacturing and commercilisation capabilities.
Since signing the deal back in March this year, Novitium has scored 13 new drug approvals (several of which were limited competition launches), completed a successful FDA GMP inspection, and reported strong EBITDA growth.
In the next 18 months, the company plans to launch 20+ new products, including those with Competitive Generic Therapy designation.
Novitium's founders, Samy Shanmugam, Chad Gassert and Vijay Thorappadi, will drive the combined company's R&D division.
As well as expanding ANI's R&D pipeline focused on niche opportunities, the transaction also expands dosage forms to include injectables and gels.
Acquiring Novitium also adds nine new customers to ANI's CDMO business and a state-of-the-art manufacturing facility in East Windsor, New Jersey, enhancing manufacturing capabilities and CDMO opportunities.
Recently raised funds also provides ANI the flexibility to integrate Novitium into the company and fund commercialisation efforts for its Purified Cortrophin Gel for multiple indications including multiple sclerosis, rheumatoid arthritis and nephrotic syndrome.
Nikhil Lalwani, President and CEO of ANI described Novitium as a "world-class R&D engine in the generic and 505 (b)(2) sectors" with a "highly compliant" manufacturing facility.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance